Greenwich LifeSciences CEO Snehal Patel buys $20,430 in shares By Investing.com

Snehal Patel, CEO and CFO of Greenwich LifeSciences, Inc. (), recently purchased company stock valued at $20,430. The transaction occurred on July 27, 2026.

Mr. Patel acquired 1,500 shares of Greenwich LifeSciences common stock at a price of $13.62 per share. The purchase comes as the stock trades near $13.45, down ~61% from its 52-week high of $34.10, with shares declining 55% over the past six months. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, though analysts maintain price targets ranging from $45 to $69. Following this direct purchase, Mr. Patel, who also serves as a director and 10% owner, beneficially owns 5,609,202 shares of the company’s common stock.

In other recent news, Greenwich LifeSciences Inc. announced modifications to its Phase III clinical trial FLAMINGO-01, following regulatory reviews by the FDA and EMA. The trial, which evaluates the GLSI-100 immunotherapy, continues without modification as recommended by the Data Safety Monitoring Board. Additionally, the European Medicines Agency has approved the inclusion of both HLA-A02 and non-HLA-A02 patients in the trial across all U.S. and European sites. This expansion means that approximately 170-180 clinical sites are now operating under the same protocol. Furthermore, the EMA has cleared the commercially manufactured GP2 for use in the trial, allowing all clinical sites to utilize the same lot. Greenwich LifeSciences also presented preliminary immune response data from 247 patients at the ASCO Annual Meeting. However, the company has delayed its Form 10-K filing due to audit coordination challenges, despite having submitted the necessary information in early February 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.